View : 680 Download: 0
Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry
- Title
- Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry
- Authors
- Kim J.-S.; Lee B.H.; Ko Y.-G.; Choi D.; Jang Y.; Min P.-K.; Yoon Y.-W.; Hong B.K.; Kwon H.M.; Ahn M.-S.; Lee S.-H.; Yoon J.H.; Lee B.K.; Kim B.O.; Kim B.-K.; Oh S.J.; Jeon D.W.; Yang J.Y.; Cho J.R.; Jung J.-H.; Ryu S.-K.; Kwon K.; Park S.H.; Byun Y.S.; Ko C.W.
- Ewha Authors
- 권기환
- SCOPUS Author ID
- 권기환
- Issue Date
- 2008
- Journal Title
- Catheterization and Cardiovascular Interventions
- ISSN
- 1522-1946
- Citation
- Catheterization and Cardiovascular Interventions vol. 72, no. 5, pp. 601 - 607
- Indexed
- SCI; SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM. © 2008 Wiley-Liss, Inc.
- DOI
- 10.1002/ccd.21700
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML